Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 2401 | 18.8 |
09:34 ET | 200 | 18.62 |
09:38 ET | 300 | 18.6 |
09:41 ET | 178 | 18.62 |
09:43 ET | 400 | 18.64 |
09:48 ET | 314 | 18.52 |
09:50 ET | 700 | 18.58 |
09:52 ET | 100 | 18.555 |
09:54 ET | 1527 | 18.66 |
09:56 ET | 400 | 18.62 |
09:57 ET | 568 | 18.645 |
09:59 ET | 600 | 18.69 |
10:01 ET | 776 | 18.725 |
10:03 ET | 400 | 18.695 |
10:06 ET | 1000 | 18.78 |
10:10 ET | 705 | 18.81 |
10:12 ET | 200 | 18.81 |
10:14 ET | 700 | 18.85 |
10:15 ET | 500 | 18.86 |
10:17 ET | 100 | 18.86 |
10:19 ET | 200 | 18.86 |
10:21 ET | 700 | 18.89 |
10:24 ET | 1100 | 18.8991 |
10:26 ET | 500 | 18.88 |
10:28 ET | 500 | 18.88 |
10:30 ET | 1091 | 18.885 |
10:32 ET | 100 | 18.885 |
10:33 ET | 400 | 18.86 |
10:35 ET | 200 | 18.885 |
10:37 ET | 1753 | 18.84 |
10:39 ET | 332 | 18.86 |
10:44 ET | 100 | 18.85 |
10:46 ET | 2013 | 18.93 |
10:48 ET | 124 | 18.918 |
10:50 ET | 1100 | 18.84 |
10:51 ET | 300 | 18.84 |
10:55 ET | 500 | 18.88 |
10:57 ET | 1045 | 18.94 |
11:02 ET | 600 | 18.94 |
11:06 ET | 600 | 18.94 |
11:11 ET | 1951 | 18.98 |
11:15 ET | 200 | 19.025 |
11:18 ET | 317 | 19.025 |
11:26 ET | 300 | 19.02 |
11:27 ET | 509 | 18.99 |
11:42 ET | 825 | 18.965 |
11:44 ET | 100 | 18.96 |
11:45 ET | 100 | 18.96 |
11:47 ET | 100 | 18.96 |
11:54 ET | 1012 | 18.96 |
11:56 ET | 100 | 18.96 |
11:58 ET | 300 | 18.96 |
12:09 ET | 610 | 18.91 |
12:14 ET | 400 | 18.89 |
12:20 ET | 661 | 18.86 |
12:21 ET | 150 | 18.8239 |
12:23 ET | 2964 | 18.9 |
12:25 ET | 400 | 18.92 |
12:27 ET | 398 | 18.92 |
12:30 ET | 600 | 18.94 |
12:32 ET | 200 | 18.94 |
12:34 ET | 202 | 18.9 |
12:36 ET | 210 | 18.895 |
12:41 ET | 1111 | 18.85 |
12:43 ET | 100 | 18.83 |
12:45 ET | 100 | 18.83 |
12:48 ET | 511 | 18.8 |
12:50 ET | 100 | 18.78 |
12:54 ET | 200 | 18.78 |
12:59 ET | 200 | 18.75 |
01:01 ET | 928 | 18.76 |
01:08 ET | 870 | 18.76 |
01:10 ET | 947 | 18.74 |
01:12 ET | 635 | 18.74 |
01:14 ET | 200 | 18.73 |
01:17 ET | 400 | 18.75 |
01:21 ET | 165 | 18.76 |
01:24 ET | 200 | 18.74 |
01:28 ET | 200 | 18.76 |
01:30 ET | 100 | 18.78 |
01:32 ET | 200 | 18.765 |
01:33 ET | 100 | 18.77 |
01:35 ET | 812 | 18.75 |
01:37 ET | 300 | 18.77 |
01:39 ET | 300 | 18.81 |
01:44 ET | 100 | 18.81 |
01:48 ET | 100 | 18.82 |
01:50 ET | 200 | 18.82 |
01:53 ET | 100 | 18.82 |
01:57 ET | 100 | 18.84 |
02:00 ET | 500 | 18.82 |
02:02 ET | 100 | 18.81 |
02:08 ET | 511 | 18.8 |
02:09 ET | 452 | 18.83 |
02:11 ET | 100 | 18.82 |
02:13 ET | 268 | 18.86 |
02:20 ET | 2251 | 18.91 |
02:22 ET | 300 | 18.93 |
02:24 ET | 300 | 18.93 |
02:26 ET | 250 | 18.95 |
02:27 ET | 1750 | 18.939 |
02:31 ET | 100 | 18.935 |
02:42 ET | 694 | 18.93 |
02:44 ET | 600 | 18.92 |
02:45 ET | 646 | 18.885 |
02:47 ET | 1000 | 18.9 |
02:49 ET | 2938 | 18.915 |
02:51 ET | 200 | 18.92 |
02:56 ET | 810 | 18.9 |
02:58 ET | 100 | 18.91 |
03:00 ET | 900 | 18.88 |
03:03 ET | 100 | 18.88 |
03:05 ET | 200 | 18.87 |
03:07 ET | 1100 | 18.86 |
03:12 ET | 200 | 18.86 |
03:14 ET | 1016 | 18.88 |
03:18 ET | 520 | 18.85 |
03:23 ET | 1465 | 18.84 |
03:25 ET | 911 | 18.84 |
03:32 ET | 500 | 18.825 |
03:34 ET | 9671 | 18.79 |
03:36 ET | 3716 | 18.79 |
03:38 ET | 200 | 18.79 |
03:41 ET | 2801 | 18.824 |
03:43 ET | 2122 | 18.815 |
03:45 ET | 4411 | 18.835 |
03:48 ET | 211 | 18.82 |
03:50 ET | 435 | 18.8 |
03:52 ET | 2694 | 18.83 |
03:54 ET | 1676 | 18.84 |
03:56 ET | 3879 | 18.87 |
03:57 ET | 4904 | 18.855 |
03:59 ET | 150144 | 18.87 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.3B | 221.5x | --- |
BioCryst Pharmaceuticals Inc | 1.3B | -5.9x | --- |
Dynavax Technologies Corp | 1.5B | 228.2x | --- |
Zai Lab Ltd | 1.7B | -5.4x | --- |
Ginkgo Bioworks Holdings Inc | 938.5M | -0.8x | --- |
MannKind Corp | 1.4B | 231.8x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 221.5x |
Price/Sales (TTM) | 4.4 |
Price/Cash Flow (TTM) | 121.6x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.